Your browser doesn't support javascript.
loading
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow, Iryna; Kent, Seamus; Herrington, William; Emberson, Jonathan; Haynes, Richard; Reith, Christina; Collins, Rory; Landray, Martin J; Gray, Alastair; Baigent, Colin; Mihaylova, Borislava.
Afiliação
  • Schlackow I; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, UK.
  • Kent S; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, UK.
  • Herrington W; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Emberson J; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Haynes R; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Reith C; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Collins R; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Landray MJ; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Gray A; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, UK.
  • Baigent C; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK; Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, UK.
  • Mihaylova B; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, UK; Centre for Primary Care and Public Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK. Electronic address: boby.mihaylova@dph.ox.ac
Kidney Int ; 96(1): 170-179, 2019 07.
Article em En | MEDLINE | ID: mdl-31005271
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Análise Custo-Benefício / Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal Crônica / Ezetimiba Tipo de estudo: Clinical_trials / Etiology_studies / Health_economic_evaluation / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Revista: Kidney Int Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Análise Custo-Benefício / Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal Crônica / Ezetimiba Tipo de estudo: Clinical_trials / Etiology_studies / Health_economic_evaluation / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Revista: Kidney Int Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido